

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

CATALENT PHARMA SOLUTIONS, INC.  
Petitioner

v.

PATHEON SOFTGELS INC.  
Patent Owner

---

Case IPR2018-00422  
Patent 9,693,979

---

**DECLARATION OF MANSOOR KHAN, R.PH., PH.D.**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## TABLE OF CONTENTS

|      |   |    |
|------|---|----|
| I.   | INTRODUCTION .....  | 1  |
| II.  | MY BACKGROUND AND QUALIFICATIONS .....  | 2  |
| III. | DOCUMENTS I CONSIDERED IN FORMULATING MY OPINIONS .....   | 6  |
| IV.  | PERSON OF ORDINARY SKILL IN THE ART .....   | 10 |
| V.   | CLAIM CONSTRUCTION .....  | 11 |
| VI.  | STATE OF THE ART BEFORE MARCH 8, 2005.....  | 17 |
|      | A. The art contradicts Mr. Draper’s implication that disclosures of “naproxen” are synonymous with “naproxen sodium”—on the contrary, naproxen and naproxen sodium are two different drugs. ....                  | 17 |
|      | B. Artisans knew that dissolving naproxen sodium in polyethylene glycol resulted in formation of naproxen-polyethylene glycol esters, producing unacceptable impurities and reduced naproxen bioavailability..... | 19 |
|      | C. Mr. Draper’s analyses depend on selecting a particular capsule size from a myriad of options.....  | 23 |
|      | D. Mr. Draper’s analyses depend on selecting a particular naproxen sodium dosage amount from a myriad of options.....   | 25 |
|      | E. The art contradicts Mr. Draper’s assertion that lactic acid and citric acid are “functional equivalents.” .....  | 26 |
| VII. | MR. DRAPER’S DECLARATION IGNORES THE STATE OF THE ART AND MISCHARACTERIZES DISCLOSURES IN THE ASSERTED REFERENCES. ....   | 31 |
|      | A. Mr. Draper mischaracterizes the disclosures in Chen.....   | 31 |
|      | 1. Mr. Draper’s assessment of Chen is based on unfounded assumptions.....   | 32 |
|      | 2. Chen discloses using lactic acid in a different context from the ’979 patent and does not suggest a composition in which lactic acid is used as claimed.....   | 35 |
|      | B. Mr. Draper mischaracterizes the disclosures in Kim. ....   | 38 |
|      | 1. Kim does not disclose compositions comprising lactic acid. ....  | 38 |
|      | 2. Mr. Draper relies on Kim’s dexibuprofen formulations to calculate naproxen sodium dosage amounts.....  | 39 |

C. Mr. Draper mischaracterizes the disclosures in Schoenhard. ....40

    1. Schoenhard does not disclose lactic acid as a deionizing agent.  
        .....41

    2. Mr. Draper’s assessment of Schoenhard is based on unfounded  
        and erroneous assumptions. ....42

VIII. MR. DRAPER MISCHARACTERIZES THE ’979 PATENT INVENTORS’  
UNEXPECTEDLY SUPERIOR RESULTS.....45

IX. CONCLUSION.....47

I, Mansoor Khan, hereby declare as follows.

**I. INTRODUCTION**

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

2. I have been retained as an expert witness on behalf of PATHEON SOFTGELS INC. (“Patheon”) for the above-captioned *inter partes* review (IPR). I am being compensated for my time in connection with this IPR at my standard consulting rate, which is \$640 per hour. I understand that the petition for *inter partes* review involves U.S. Patent No. 9,693,979 (“the ’979 Patent”), EX1003. I understand that the petition was filed by CATALENT PHARMA SOLUTIONS, INC. (“Catalent”).

3. I understand that the ’979 patent resulted from U.S. Application No. 15/159,972 (“the ’972 application”), filed on May 20, 2016, naming Nachiappan Chidambaram and Aqeel Fatmi as inventors. I understand that the ’972 application is a continuation application that relates to a series of previous applications. I also understand that the earliest possible priority date for the ’979 Patent is March 8, 2005, the filing date of U.S. Provisional Patent Application No. 60/659,679, and I refer to this date throughout this declaration. The ’979 patent was issued on July 4, 2017, from the ’972 application. I further understand that, according to the USPTO records, the ’979 patent is currently assigned to Patheon.

4. In preparing this Declaration, I have reviewed the '979 patent and each of the documents cited herein in light of the general knowledge in the art before March 8, 2005. In formulating my opinions, I have relied upon my experience, education, and knowledge in the relevant art. In formulating my opinions, I have also considered the viewpoint of a person of ordinary skill in the art (“POSA”)—*i.e.*, a person of ordinary skill in the field of oral formulations including soft gelatin capsules—prior to March 8, 2005.

## II. MY BACKGROUND AND QUALIFICATIONS

5. I am currently Professor and Vice Dean of the College of Pharmacy at Texas A&M University (College Station, TX). I am also interim Department Head of Pharmaceutical Sciences and the Director of the Formulations Design and Development Core Laboratory at Texas A&M. My qualifications and credentials are more fully set forth in my *curriculum vitae*, provided as PSG1002.

6. I am an expert in the field of pharmaceutical formulations—including soft gelatin capsules—and have been since before March 8, 2005. I have been actively working in the field of pharmaceutical formulations since the 1980s, and have gained significant experience in the field while studying and carrying out the design of numerous types of formulations. My expertise includes thorough knowledge and understanding of soft gelatin capsule formulations.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.